Fresenius Kabi is a global healthcare company based in Singapore that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients.
Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies, and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for the collection of blood components and extracorporeal therapies.
Fresenius Kabi offers a broad range of intravenously administered generic drugs across a wide array of therapeutic categories: oncology drugs, anesthetics & analgesics, anti-infectives, critical care drugs. For the administration of these products, the company provides related medical devices.
For infusion therapy, Fresenius Kabi offers products for fluid and blood volume replacement. Moreover, Fresenius Kabi’s product portfolio includes a broad range of infusion technologies as well as disposables for the delivery of medication for all pharmaceuticals administered via the vein.
With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.